US FDA issues Institutional Review Board (IRB) Written Procedures

Final Guidance for Institutions and IRBs effective May 2018

This guidance has been prepared jointly by the Department of Health and Human Services (HHS) Office for Human Research Protections (OHRP) and the Food and Drug Administration (FDA). To enhance human subject protection and reduce regulatory burden, OHRP and FDA have been actively working to harmonize the Agencies’ regulatory requirements and guidance for human subject research. This guidance document was developed as a part of these efforts.

Read more online
Copyright Widler & Schiemann AG 2022. All Rights Reserved. /